BioCentury | Sep 10, 2019
Emerging Company Profile

Trucode: advancing nuclease-free, viral vector-independent gene therapy

After bouncing around in several different companies, Peter Glazer’s peptide nucleic acid gene editing technology is getting another shot at development with the launch of Trucode. This time around, the technology is more advanced and...
BC Extra | Jul 30, 2019
Company News

July 29 Company Quick Takes: Dupixent sales boost Sanofi; plus Twist, J&J, Alkermes and more

Despite multibillion dollar impairment, Sanofi beats on 2Q19 earnings  Sanofi (Euronext:SAN; NASDAQ:SNY) reported 2Q19 sales of €496 million from dermatitis and asthma drug Dupixent dupilumab, beating the Street's estimate of €411 million. The pharma also...
BC Extra | Aug 1, 2017
Company News

CRISPR names EVP and head of R&D

Gene editing company CRISPR Therapeutics AG (NASDAQ:CRSP) named Tony Ho EVP and head of R&D as the company moves closer to the clinic. Ho was SVP and head of oncology integration and innovation at AstraZeneca...
Items per page:
1 - 3 of 3